false

Jenny Zilberberg

Jenny Zilberberg has more than 20 years of combined experience across academia and biotechnology, with expertise in translational immunology, cancer immunotherapy, and biomarker strategy. Most recently, she served as Head of Research at Imvax, where she led preclinical development and biomarker activities for the company’s immunotherapy platform and lead glioblastoma program. At Precision, Jenny partners with sponsors to design and implement biomarker and bioanalytical solutions that support clinical development across oncology and autoimmune diseases.

• Read: Receptor Occupancy in the Era of Multispecific Therapeutics

  Translational Research - Lab Services

  Receptor Occupancy in the Era of Multispecific Therapeutics

  Jul 28, ‘26 | 6 min read

  • 

  • Deborah P.

    Jenny Z.

  Discover

Loading...

You've reach the end Back to top